Silvia
Jiménez Cabrera
Profesora Asociada CC. Salud
Hospital Duran i Reynals
Barcelona, EspañaPublications in collaboration with researchers from Hospital Duran i Reynals (1)
2019
-
Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)
Annals of Oncology, Vol. 30, Núm. 4, pp. 612-620